Lord, Jonathan M

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 786

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 698

The role of lifestyle modification in polycystic ovary syndrome

Norman, R. J., Davies, M. J., Lord, J., & Moran, L. J. (2002) · Trends in Endocrinology & Metabolism

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 326

The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome

Lord, J., Thomas, R., Fox, B., Acharya, U., & Wilkin, T. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 158

The Effect of Metformin on Fat Distribution and the Metabolic Syndrome in Women With Polycystic Ovary Syndrome–A Randomised, Double-Blind, Placebo-Controlled Trial

Lord, J., Thomas, R., Fox, B., Acharya, U., & Wilkin, T. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 113